medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-19-49-53medalphabet-2133Research ArticleСтатьиСердечные биомаркеры у пациентов после химиотерапииBiomarkers in patients after chemotherapyhttps://orcid.org/0000-0002-1675-4216АкилджоновФ. Р.AkildzhonovF. R.

Акилджонов Фирдавсджон Рустамджонович, ординатор

Москва

Akildzhonov Firdavsdzhon R., resident physician

Moscow

fidavs96_tths@mail.ruhttps://orcid.org/0000-0001-7016-7541БузиашвилиЮ. И.BuziashviliJ. I.

Бузиашвили Юрий Иосифович, д. м. н., проф., акад. РАН, зав. клинико‑диагностическим отделением

Москва

Buziashvili Juriy I., DM Sci, professor, academician of RAS, head of Clinical and Diagnostic Dept

Moscow

СтилидиИ. С.StilidiI. S.

Стилиди Иван Сократович, д. м. н. проф., акад. РАН, директор

Москва

Stilidi Ivan S., DM Sci, professor, academician of RAS, director

Moscow

https://orcid.org/0000-0002-5422-2069АсымбековаЭ. У.AsymbekovaE. U.

Асымбекова Эльмира Уметовна, д. м. н., в. н. с. клинико‑диагностического отделения

Москва

Asymbekova El’mira U., DM Sci, freelance researcher at Clinical and Diagnostic Dept.

Moscow

https://orcid.org/0000-0001-7728-9533АртамоноваЕ. В.ArtamonovaE. V.

Артамонова Елена Владимировна, д. м. н., в. н. с. отделения изучения новых противоопухолевых лекарств

Москва

Artamonova Elena V., DM Sci, freelance researcher at Dept of New Anticancer Drugs Studies

Moscow

ФГБУ «Национальный медицинский исследовательский центр сердечно-сосудистой хирургии имени А. Н. Бакулева» Минздрава РоссииРоссияNational Medical Research Center for Cardiovascular Surgery n.a. A. N. BakulevRussian Federation202118082021019Диагностика и онкотерапия (2)4953Copyright © Акилджонов Ф.Р., Бузиашвили Ю.И., Стилиди И.С., Асымбекова Э.У., Артамонова Е.В., 20212021Акилджонов Ф.Р., Бузиашвили Ю.И., Стилиди И.С., Асымбекова Э.У., Артамонова Е.В.Akildzhonov F.R., Buziashvili J.I., Stilidi I.S., Asymbekova E.U., Artamonova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2133

Наряду с быстрым развитием молекулярно-генетического тестирования, иммунотерапии и таргетной противоопухолевой терапии в онкологии риск кардиотоксичности, связанный с химиотерапией, остается краеугольным камнем, который непосредственно влияет на выживаемость и качество жизни пациентов после терапии. Повышенные уровни тропонина, BNP/NT-proBNP, миелопероксидазы и D-димера были связаны с увеличением смертности от всех причин у пациентов с онкологическими заболеваниями и были показаны в многочисленных исследованиях их значимости для прогнозирования риска сердечной недостаточности и повреждения миокарда, связанного с химиотерапией. Специфические диагностические алгоритмы особенно важны для стратификации риска, мониторинга и долгосрочного наблюдения за онкологическими больными, получающие химиотерапию. Биомаркеры являются основой для диагностики острых и хронических заболеваний сердца. Однако их роль в своевременном выявлении и мониторинге кардиотоксичности недостаточно изучена. Таким образом, клиницисты должны выявлять нежелательные явления на ранней стадии, стремясь принять соответствующие профилактические меры до возникновения постоянной или необратимой дисфункции сердца. В динамично развивающейся кардиологии биомаркеры являются ключевым инструментом оценки риска, диагностики и мониторинга кардиотоксичности, ассоциированной химиотерапией. Комплексное взаимодействие таких отраслей медицины, как онкология, онкотерапия и кардиология, указывает на необходимость мультидисциплинарного кардио-онкологического подхода для обеспечения оптимального качества лечения.

Along with the rapid development of molecular genetic testing, immunotherapy and targeted antitumor therapy in Oncology, the risk of cardiotoxicity associated with chemotherapy remains a keystone that directly affects the survival and quality of life of patients after therapy. Elevated levels of troponin, BNP/NT-proBNP, myeloperoxidase, and D-dimer have been associated with increased all-cause mortality in cancer patients and have been shown in numerous studies to predict the risk of heart failure and myocardial damage associated with chemotherapy. Specifi diagnostic algorithms are particularly important for risk stratifiation, monitoring, and long-term follow-up of cancer patients receiving chemotherapy. Biomarkers are the basis for diagnosing acute and chronic heart diseases. However, their role in the timely detection and monitoring of cardiotoxicity is not well understood. Thus, clinicians should identify adverse effects at an early stage, seeking to take appropriate preventive measures before the occurrence of a permanent or irreversible dysfunction of the heart. In dynamic cardiology, biomarkers are a key tool for risk assessment, diagnosis, and monitoring of cancer-related cardiotoxicity and cancer therapy. The complex interaction of such branches of medicine as oncology, oncotherapy and cardiology indicates the need for a multi-disciplinary cardio-oncological approach to ensure optimal quality of treatment

биомаркерытропонинынатрийуретические пептидыД‑димерbiomarkerstroponinsnatriuretic peptidesD‑dimerReferencesЗаридзе Д. Г., Максимович Д. М. Профилактика злокачественных новообразований. Успехи молекулярной онкологии. 2017; 4 (2): 8–25. https://doi.org/10.17650/2313–805X-2017–4–2–8–25Zaridze D. G., Maksimovich D. M. Prevention of malignant neoplasms. Advances in Molecular Oncology. 2017; 4 (2): 8–25. (In Russ.) https://doi.org/10.17650/2313–805X-2017–4–2–8–25Moslehi J., Amgalan D., Kitsis R. Grounding Cardio-Oncology in Basic and Clinical Science. Circulation. 2017; 136 (1): 3–5. https://doi.org/10.1161/circulationaha.117.025393Moslehi J., Amgalan D., Kitsis R. Grounding Cardio-Oncology in Basic and Clinical Science. Circulation. 2017; 136 (1): 3–5. https://doi.org/10.1161/circulationaha.117.025393Ferrell B., Temel J., Temin S. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017; 35 (1): 96–112. https://doi.org/:10.1200/JCO.2016.70.1474Ferrell B., Temel J., Temin S. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017; 35 (1): 96–112. https://doi.org/:10.1200/JCO.2016.70.1474Zamorano J., Lancellotti P., Rodriguez Muñoz D. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37 (36): 2768–2801. https://doi.org/:10.1093/eurheartj/ehw211Zamorano J., Lancellotti P., Rodriguez Muñoz D. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37 (36): 2768–2801. https://doi.org/:10.1093/eurheartj/ehw211Семиглазова Т. Ю., Телетаева Г. М., Козявин Н. А., Загатина А. В. Диагностика и профилактика кардиотоксичности у больных раком молочной железы с позиций онколога и кардиолога. Опухоли женской репродуктивной системы. 2017; 13 (3): 17–27. https://doi.org/10.17650/1994–4098–2017–13–3–17–27Semiglazova T. Yu., Teletaeva G. M., Kozyavin N. A., Zagatina A. V. Diagnosis and prevention of cardiotoxicity in patients with breast cancer from the standpoint of an oncologist and a cardiologist. Tumors of female reproductive system. 2017;13 (3): 17–27. (In Russ.) https://doi.org/10.17650/1994–4098–2017–13–3–17–27Sweeney M., Yiu A., Lyon A. Cardiac Atrophy and Heart Failure In Cancer. Card Fail Rev. 2017; 3 (1): 62–65. https://doi.org/:10.15420/cfr.2017:3:2Sweeney M., Yiu A., Lyon A. Cardiac Atrophy and Heart Failure In Cancer. Card Fail Rev. 2017; 3 (1): 62–65. https://doi.org/:10.15420/cfr.2017:3:2Burch G., Phillips J., Ansari A. The cachetic heart. A clinico-pathologic, electrocardiographic and roentgenographic entity. Dis Chest. 1968; 54 (5): 403–409. https://doi.org/10.1378/chest.54.5.403Burch G., Phillips J., Ansari A. The cachetic heart. A clinico-pathologic, electrocardiographic and roentgenographic entity. Dis Chest. 1968; 54 (5): 403–409. https://doi.org/10.1378/chest.54.5.403Pavo N., Raderer M., Hülsmann M. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart. 2015; 101 (23): 1874–1880. https://doi.org/10.1136/heartjnl-2015–307848Pavo N., Raderer M., Hülsmann M. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart. 2015; 101 (23): 1874–1880. https://doi.org/10.1136/heartjnl-2015–307848De Vito P. Atrial natriuretic peptide: an old hormone or a new cytokine? Peptides. 2014; 58: 108–116. https://doi.org/10.1016/j.peptides.2014.06.011De Vito P. Atrial natriuretic peptide: an old hormone or a new cytokine? Peptides. 2014; 58: 108–116. https://doi.org/10.1016/j.peptides.2014.06.011Meijers W., Maglione M., Bakker S. Heart Failure Stimulates Tumor Growth by Circulating Factors. Circulation. 2018; 138 (7): 678–691. https://doi.org/10.1161/CIRCULATIONAHA.117.030816Meijers W., Maglione M., Bakker S. Heart Failure Stimulates Tumor Growth by Circulating Factors. Circulation. 2018; 138 (7): 678–691. https://doi.org/10.1161/CIRCULATIONAHA.117.030816Shi C., van der Wal H., Silljé H. Tumour biomarkers: association with heart failure outcomes. J Intern Med. 2020; 10.1111/joim.13053. https://doi.org/10.1111/joim.13053Shi C., van der Wal H., Silljé H. Tumour biomarkers: association with heart failure outcomes. J Intern Med. 2020; 10.1111/joim.13053. https://doi.org/10.1111/joim.13053Meijers W., de Boer R., van Veldhuisen D. Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH. Eur J Heart Fail. 2015; 17 (12): 1271–1282. https://doi.org/10.1002/ejhf.407Meijers W., de Boer R., van Veldhuisen D. Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH. Eur J Heart Fail. 2015; 17 (12): 1271–1282. https://doi.org/10.1002/ejhf.407Sharma S., Jackson P., Makan J. Cardiac troponins. Journal of Clinical Pathology. 2004; 57 (10): 1025–1026. https://doi.org/10.1136/jcp.2003.015420Sharma S., Jackson P., Makan J. Cardiac troponins. Journal of Clinical Pathology. 2004; 57 (10): 1025–1026. https://doi.org/10.1136/jcp.2003.0154202015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. 2015; 37 (3): 267–315. https://doi.org/10.1093/eurheartj/ehv320.2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. 2015; 37 (3): 267–315. https://doi.org/10.1093/eurheartj/ehv320.Thygesen K., Alpert J., Jaffe A. Fourth Universal Defiition of Myocardial Infarction Circulation. 2018; 138 (20): 618–651. https://doi.org/10.1161/CIR.0000000000000617Thygesen K., Alpert J., Jaffe A. Fourth Universal Defiition of Myocardial Infarction Circulation. 2018; 138 (20): 618–651. https://doi.org/10.1161/CIR.0000000000000617Tanindi A., Cemri M. Troponin elevation in conditions other than acute coronary syndromes. Vasc Health Risk Manag. 2011; 7: 597–603. https://doi.org/10.2147/VHRM.S 24509Tanindi A., Cemri M. Troponin elevation in conditions other than acute coronary syndromes. Vasc Health Risk Manag. 2011; 7: 597–603. https://doi.org/10.2147/VHRM.S 24509Myhre P., O’Meara E., Claggett B. Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction. Circulation Heart Fail. 2018; 11 (11): e005312. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005312Myhre P., O’Meara E., Claggett B. Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction. Circulation Heart Fail. 2018; 11 (11): e005312. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005312Eggers K., Jernberg T., Lindahl B. Cardiac Troponin Elevation in Patients Without a Specifi Diagnosis. J Am Coll Cardiol. 2019; 73 (1): 1–9. https://doi.org/10.1016/j.jacc.2018.09.082Eggers K., Jernberg T., Lindahl B. Cardiac Troponin Elevation in Patients Without a Specifi Diagnosis. J Am Coll Cardiol. 2019; 73 (1): 1–9. https://doi.org/10.1016/j.jacc.2018.09.082Bracun V., Aboumsallem J., van der Meer P., de Boer R. Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues. Curr Oncol Rep. 2020; 22 (7): 67. https://doi.org/10.1007/s11912–020–00930-xBracun V., Aboumsallem J., van der Meer P., de Boer R. Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues. Curr Oncol Rep. 2020; 22 (7): 67. https://doi.org/10.1007/s11912–020–00930-xKy B., Putt M, Sawaya H. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014; 63 (8): 809–816. https://doi.org/:10.1016/j.jacc.2013.10.061Ky B., Putt M, Sawaya H. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014; 63 (8): 809–816. https://doi.org/:10.1016/j.jacc.2013.10.061Cardinale D., Sandri M., Colombo A. Prognostic value of troponin I in cardiac risk stratifiation of cancer patients undergoing high-dose chemotherapy. Circulation. 2004; 109 (22): 2749–2754. https://doi.org/10.1161/01.CIR.0000130926.51766.CCCardinale D., Sandri M., Colombo A. Prognostic value of troponin I in cardiac risk stratifiation of cancer patients undergoing high-dose chemotherapy. Circulation. 2004; 109 (22): 2749–2754. https://doi.org/10.1161/01.CIR.0000130926.51766.CCBlaes A., Rehman A., Vock D. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy. Vasc Health Risk Manag. 2015; 11: 591–594. https://doi.org/10.2147/VHRM.S 89842Blaes A., Rehman A., Vock D. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy. Vasc Health Risk Manag. 2015; 11: 591–594. https://doi.org/10.2147/VHRM.S 89842Kitayama H., Kondo T., Sugiyama J. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients. Breast Cancer. 2017; 24 (6): 774–782. https://doi.org/10.1007/s12282–017–0778–8Kitayama H., Kondo T., Sugiyama J. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients. Breast Cancer. 2017; 24 (6): 774–782. https://doi.org/10.1007/s12282–017–0778–8Zhang C., Pei X., Song F. Early anthracycline-induced cardiotoxicity monitored by echocardiographic Doppler parameters combined with serum hs-cTnT. Echocardiography. 2017; 34 (11): 1593–1600. https://doi.org/10.1111/echo.13704Zhang C., Pei X., Song F. Early anthracycline-induced cardiotoxicity monitored by echocardiographic Doppler parameters combined with serum hs-cTnT. Echocardiography. 2017; 34 (11): 1593–1600. https://doi.org/10.1111/echo.13704Mahjoob M., Sheikholeslami S., Dadras M. Prognostic Value of Cardiac Biomarkers Assessment in Combination with Myocardial 2D Strain Echocardiography for Early Detection of Anthracycline-Related Cardiac Toxicity. Cardiovasc Hematol Disord Drug Targets. 2020; 20 (1): 74–83. https://doi.org/10.2174/1871529X19666190912150942Mahjoob M., Sheikholeslami S., Dadras M. Prognostic Value of Cardiac Biomarkers Assessment in Combination with Myocardial 2D Strain Echocardiography for Early Detection of Anthracycline-Related Cardiac Toxicity. Cardiovasc Hematol Disord Drug Targets. 2020; 20 (1): 74–83. https://doi.org/10.2174/1871529X19666190912150942Tan L., Lyon A. Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment. Curr Treat Options Cardiovasc Med. 2018; 20 (7): 55. https://doi.org/10.1007/s11936–018–0641 -zTan L., Lyon A. Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment. Curr Treat Options Cardiovasc Med. 2018; 20 (7): 55. https://doi.org/10.1007/s11936–018–0641 -zMoslehi J., Salem J., Sosman J., Lebrun-Vignes B., Johnson D. Reporting of immune checkpoint inhibitor-associated myocarditis – Authors’ reply. Lancet. 2018; 392 (10145): 384–385. https://doi.org/10.1016/S 0140–6736(18)31556–3Moslehi J., Salem J., Sosman J., Lebrun-Vignes B., Johnson D. Reporting of immune checkpoint inhibitor-associated myocarditis – Authors’ reply. Lancet. 2018; 392 (10145): 384–385. https://doi.org/10.1016/S 0140–6736(18)31556–3Mahmood S., Fradley M., Cohen J. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018; 71 (16): 1755–1764. https://doi.org/10.1016/j.jacc.2018.02.037Mahmood S., Fradley M., Cohen J. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018; 71 (16): 1755–1764. https://doi.org/10.1016/j.jacc.2018.02.037Dolladille C., Ederhy S., Allouche S. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020; 8 (1): e000261. https://doi.org/10.1136/jitc-2019–000261Dolladille C., Ederhy S., Allouche S. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020; 8 (1): e000261. https://doi.org/10.1136/jitc-2019–000261Gulati G., Heck S., Ree A. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled,double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016; 37(21): 1671–1680. https://doi.org/10.1093/eurheartj/ehw022Gulati G., Heck S., Ree A. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled,double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016; 37(21): 1671–1680. https://doi.org/10.1093/eurheartj/ehw022Cardinale D., Ciceri F., Latini R. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer. 2018; 94: 126–137. https://doi.org/10.1016/j.ejca.2018.02.005Cardinale D., Ciceri F., Latini R. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer. 2018; 94: 126–137. https://doi.org/10.1016/j.ejca.2018.02.005Pareek N., Cevallos J., Moliner P. Activity and outcomes of a cardio-oncology service in the United Kingdom-a fie-year experience. Eur J Heart Fail. 2018; 20 (12): 1721–1731. https://doi.org/10.1002/ejhf.1292Pareek N., Cevallos J., Moliner P. Activity and outcomes of a cardio-oncology service in the United Kingdom-a fie-year experience. Eur J Heart Fail. 2018; 20 (12): 1721–1731. https://doi.org/10.1002/ejhf.1292Kappel C., Rushton M., Johnson C. Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: an observational cohort study. Curr Oncol. 2019; 26 (3): e322–e327. https://doi.org/10.3747/co.26.4509Kappel C., Rushton M., Johnson C. Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: an observational cohort study. Curr Oncol. 2019; 26 (3): e322–e327. https://doi.org/10.3747/co.26.4509Ponikowski P., Voors A., Anker S. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2016; 37 (27): 2129–2200. https://doi.org/10.1093/eurheartj/ehw128Ponikowski P., Voors A., Anker S. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2016; 37 (27): 2129–2200. https://doi.org/10.1093/eurheartj/ehw128Mueller C., McDonald K., de Boer R. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019; 21 (6): 715–731. https://doi.org/10.1002/ejhf.1494Mueller C., McDonald K., de Boer R. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019; 21 (6): 715–731. https://doi.org/10.1002/ejhf.1494Wang Y., Chen S., Ren L. Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity. Oncol Lett. 2016; 11 (5): 3483–3492. https://doi.org/10.3892/ol.2016.4424Wang Y., Chen S., Ren L. Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity. Oncol Lett. 2016; 11 (5): 3483–3492. https://doi.org/10.3892/ol.2016.4424Pavo N., Raderer M., Hülsmann M. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart. 2015; 101 (23): 1874–1880. https://doi.org/10.1136/heartjnl-2015–307848Pavo N., Raderer M., Hülsmann M. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart. 2015; 101 (23): 1874–1880. https://doi.org/10.1136/heartjnl-2015–307848Lenihan D., Stevens P., Massey M. The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study. J Card Fail. 2016; 22 (6): 433–438. https://doi.org/10.1016/j.cardfail.2016.04.003Lenihan D., Stevens P., Massey M. The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study. J Card Fail. 2016; 22 (6): 433–438. https://doi.org/10.1016/j.cardfail.2016.04.003Bouwer N., Liesting C., Kofflrd M. NT-proBNP correlates with LVEF decline in HER 2-positive breast cancer patients treated with trastuzumab. Cardiooncology. 2019; 5:4. https://doi.org/10.1186/s40959–019–0039–4Bouwer N., Liesting C., Kofflrd M. NT-proBNP correlates with LVEF decline in HER 2-positive breast cancer patients treated with trastuzumab. Cardiooncology. 2019; 5:4. https://doi.org/10.1186/s40959–019–0039–4Demissei B., Hubbard R., Zhang L. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. J Am Heart Assoc. 2020; 9 (2): e014708. https://doi.org/10.1161/JAHA.119.014708Demissei B., Hubbard R., Zhang L. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. J Am Heart Assoc. 2020; 9 (2): e014708. https://doi.org/10.1161/JAHA.119.014708Anatoliotakis N., Deftereos S., Bouras G. Myeloperoxidase: expressing inflmmation and oxidative stress in cardiovascular disease. Curr Top Med Chem. 2013; 13 (2): 115–138. https://doi.org/10.2174/1568026611313020004Anatoliotakis N., Deftereos S., Bouras G. Myeloperoxidase: expressing inflmmation and oxidative stress in cardiovascular disease. Curr Top Med Chem. 2013; 13 (2): 115–138. https://doi.org/10.2174/1568026611313020004Florescu D., Nistor D. Therapy-induced cardiotoxicity in breast cancer patients: a well-known yet unresolved problem. Discoveries (Craiova). 2019; 7 (1): e89. https://doi.org/10.15190/d.2019.2Florescu D., Nistor D. Therapy-induced cardiotoxicity in breast cancer patients: a well-known yet unresolved problem. Discoveries (Craiova). 2019; 7 (1): e89. https://doi.org/10.15190/d.2019.2Finkelman B., Putt M., Wang T. Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer. J Am Coll Cardiol. 2017; 70 (2): 152–162.https://doi.org/10.1016/j.jacc.2017.05.019Finkelman B., Putt M., Wang T. Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer. J Am Coll Cardiol. 2017; 70 (2): 152–162.https://doi.org/10.1016/j.jacc.2017.05.019Minasian L., Dimond E., Davis M. The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity. JACC Cardio Oncol. 2019; 1 (1): 105–113. https://doi.org/10.1016/j.jaccao.2019.08.007Minasian L., Dimond E., Davis M. The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity. JACC Cardio Oncol. 2019; 1 (1): 105–113. https://doi.org/10.1016/j.jaccao.2019.08.007Kikuchi R., Shah N., Dent S. Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime? J Clin Med. 2020; 9 (4): 896. Published 2020 Mar 25. https://doi.org/10.3390/jcm9040896Kikuchi R., Shah N., Dent S. Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime? J Clin Med. 2020; 9 (4): 896. Published 2020 Mar 25. https://doi.org/10.3390/jcm9040896Slivnick J., Vallakati A., Addison D., Wallner A. Personalized Approach to Cancer Treatment-Related Cardiomyopathy. Curr Heart Fail Rep. 2020; 17 (2): 43–55. https://doi.org/10.1007/s11897–020–00453–3Slivnick J., Vallakati A., Addison D., Wallner A. Personalized Approach to Cancer Treatment-Related Cardiomyopathy. Curr Heart Fail Rep. 2020; 17 (2): 43–55. https://doi.org/10.1007/s11897–020–00453–3

The authors declare that there are no conflicts of interest present.